Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ELCC 2026 and Lung Cancer View overview page

BECOME trial: OS results of becotarug and osimertinib in EGFR exon 20 insertion-mutated NSCLC 0:56
BECOME trial: OS results of becotarug and osimertinib in EGFR exon 20 insertion-mutated NSCLC
Adrian Sacher • 27 Mar 2026
Optimal sequencing of EGFR-targeted therapies for NSCLC 2:03
Optimal sequencing of EGFR-targeted therapies for NSCLC
Nicolas Girard • 28 Mar 2026
Updated results from PALOMA-2: first-line subcutaneous amivantamab plus lazertinib in NSCLC 2:19
Updated results from PALOMA-2: first-line subcutaneous amivantamab plus lazertinib in NSCLC
Nicolas Girard • 28 Mar 2026
Local consolidation and systemic therapy combinations in EGFR-mutated lung cancer 0:51
Local consolidation and systemic therapy combinations in EGFR-mutated lung cancer
Saumil Ghandi • 27 Mar 2026
Local consolidative therapy with osimertinib: NorthStar trial background and secondary analysis 1:46
Local consolidative therapy with osimertinib: NorthStar trial background and secondary analysis
Saumil Ghandi • 27 Mar 2026
Beamion LUNG-1: zongertinib in treatment-naïve HER2-mutant NSCLC and in those with brain metastases 1:10
Beamion LUNG-1: zongertinib in treatment-naïve HER2-mutant NSCLC and in those with brain metastases
Adrian Sacher • 27 Mar 2026
Calderasib, a novel KRAS G12C-off inhibitor in NSCLC: insights from the KANDLELIT-001 trial 1:47
Calderasib, a novel KRAS G12C-off inhibitor in NSCLC: insights from the KANDLELIT-001 trial
Adrian Sacher • 27 Mar 2026
Toxicity management with bispecific T-cell engagers in lung cancer 1:08
Toxicity management with bispecific T-cell engagers in lung cancer
May-Lucie Meyer • 27 Mar 2026
T-cell engagers in NSCLC and mesothelioma 0:34
T-cell engagers in NSCLC and mesothelioma
May-Lucie Meyer • 27 Mar 2026
Neoadjuvant vs perioperative immunotherapy in resectable NSCLC 1:10
Neoadjuvant vs perioperative immunotherapy in resectable NSCLC
Nicolas Girard • 28 Mar 2026
Opportunities and challenges in the exon 20 insertion space in lung cancer 1:47
Opportunities and challenges in the exon 20 insertion space in lung cancer
Adrian Sacher • 27 Mar 2026
Current and emerging HER2-targeted therapies in NSCLC 2:43
Current and emerging HER2-targeted therapies in NSCLC
Nicolas Girard • 28 Mar 2026
Targeted therapy options by BRAF mutation class in lung cancer 2:07
Targeted therapy options by BRAF mutation class in lung cancer
Mariana Brandao • 28 Mar 2026
Multimodal treatment approaches for resectable NSCLC 0:56
Multimodal treatment approaches for resectable NSCLC
Rene Petersen • 26 Mar 2026
Surgery for SCLC: current indications and future options 0:49
Surgery for SCLC: current indications and future options
Rene Petersen • 26 Mar 2026
How does disease biology vary across BRAF mutation classes in lung cancer? 3:08
How does disease biology vary across BRAF mutation classes in lung cancer?
Mariana Brandao • 28 Mar 2026
The content of VJOncology is intended for healthcare professionals